Skip to main content
UNITED THERAPEUTICS Corp logo

UNITED THERAPEUTICS Corp — Investor Relations & Filings

Ticker · UTHR ISIN · US91307C1027 LEI · 5299005C4HZL4UWROC14 US Manufacturing
Open in API
Filings indexed 2,877 across all filing types
Latest filing 2025-11-25 Director's Dealing
Country US United States of America
Listing US UTHR

About UNITED THERAPEUTICS Corp

https://www.unither.com/

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of therapies for chronic and life-threatening conditions. The company's primary therapeutic areas include pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also develops treatments for pediatric neuroblastoma. In addition to its pharmaceutical pipeline, United Therapeutics is actively engaged in research and development of technologies to manufacture transplantable organs and tissues, aiming to address the shortage of donor organs.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2025-11-25 English
Director's Dealing 2025
Director's Dealing Classification · 100% confidence The document text primarily consists of detailed records of share transactions by Martine Rothblatt, who is identified as Founder, Chairperson, and CEO. The text includes dates, number of shares, and transaction details such as shares exercised via vested options. There is no indication of financial statements, management discussion, or report content. The document is a report of personal share transactions by a company director/executive, which fits the definition of Director's Dealing filings. The length of the document (5721 characters) supports it being a detailed insider transaction report rather than a brief announcement or certification. Therefore, the appropriate classification is Director's Dealing (DIRS).
2025-11-25 English
Director's Dealing 2025
Director's Dealing Classification · 100% confidence The document text primarily consists of detailed records of share transactions by Martine Rothblatt, the founder, chairperson, and CEO of United Therapeutics Corp. It lists dates, number of shares, and transaction details such as shares exercised via vested options and payments made via common shares. There is no indication of financial statements, management discussion, or report summaries. The content matches the description of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document length is 5627 characters, which is sufficient to contain detailed transaction data rather than a brief announcement. Therefore, the document is best classified as a Director's Dealing report.
2025-11-24 English
PRIMARY DOCUMENT
Director's Dealing
2025-11-21 English
Director's Dealing 2025
Director's Dealing Classification · 95% confidence The document text primarily consists of detailed records of share transactions by Martine Rothblatt, who is identified as Founder, Chairperson, and CEO of United Therapeutics Corp. The text includes dates, number of shares, and transaction details such as shares exercised via vested options. There is no indication of financial statements, management discussion, earnings data, or other report content. The document is a report of personal share transactions by a company director/executive, which fits the definition of Director's Dealing (DIRS). The document length is about 5,533 characters, which is sufficient to contain detailed transaction data rather than a brief announcement. Therefore, the classification is DIRS with high confidence.
2025-11-21 English
PRIMARY DOCUMENT
Director's Dealing
2025-11-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.